Le Lézard
Classified in: Health
Subjects: PDT, MAT

Cativa CBD Introduces Two New CBD-infused Drinks


PORTSMOUTH, Va., May 6, 2020 /PRNewswire-PRWeb/ -- Cativa Health ("Cativa CBD"), a science-based cannabidiol (CBD) brand revolutionizing the wellness and CBD industries, announced the launch of its CBD-infused Iced Coffee and a CBD Hibiscus Tea. The drinks, part of the brand's Balance product line, contain 20 mg of THC-free CBD per can.

"Our mission at Cativa CBD is to bring health and wellness to people through science," said Luisa Escobar Worrell, the Chief Operating Officer of Cativa CBD. "These two new drinks continue our mission and provide a new means to live healthier and happier lives."

The Balance CBD Iced Coffee is made with 100% Colombian Arabica beans without preservatives or additives. The coffee is sweetened with cane sugar and infused with broad-spectrum CBD.

It's sister product, Cativa CBD's Balance CBD Hibiscus Tea, brings a refreshing taste of hibiscus blossoms mixed with hints of fruit such as apple, papaya, and elderberries. This freshly brewed tea is infused with nitrogen to preserve natural flavors while maintaining the benefits of CBD.

"Our teams are continuing to work diligently to bring new products to market that are innovative in delivering the benefits of CBD," continued Worrell. "We strive to provide products that promote holistic wellness, including relaxation and relief, while elevating the CBD industry as a whole."

Alongside these beverages, Cativa offers the following to provide a holistic approach to CBD health:

For more information about Cativa CBD and to order products, please visit http://www.cativacbd.com. Samples, photos, and interviews with leadership are available upon request.

ABOUT CATIVA
Cativa CBD is a science-backed CBD brand committed to creating products that work. Founded in 2018, Cativa CBD is dedicated to using the latest in cutting-edge technology and zero-THC CBD isolates. Cativa CBD was founded with a simple mission: to combine the power of science and the promise of nature to deliver wellness and health. We believe in the untapped potential of CBD to heal the mind and body. And, we are committed to building a limitless future where technology and nature work together. We are passionate about science, sustainability, and promoting human health and the environment. And, we are passionate about you. Cativa is sold at retailers and via http://www.CativaCBD.com.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat, or cure any disease.

LEGAL DISCLOSURE
Cativa CBD does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US CSA). The company sells and distributes hemp-based products. Cannabidiol is a natural constituent of hemp.

Media Contacts
Allyson Markey, PR Manager
[email protected]    
858-442-2167

 

SOURCE Cativa CBD


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: